Rasonque
-
Health & Lifestyle
Daraxonrasib Pancreatic Cancer Trial: Tumours Shrank in 60.7% of Patients
A daraxonrasib pancreatic cancer combination shrank tumours in 60.7% of previously untreated patients whose disease had spread, according to updated…
Read More »